AreteiaTx

Areteia Therapeutics is a clinical-stage biotechnology company focused on developing and delivering the first oral drug for eosinophilic asthma. Their lead investigational candidate, dexpramipexole, is a first-in-class oral medicine that inhibits the maturation of eosinophils, the white blood cells that contribute to inflammation in asthma. The company is committed to putting respiratory patients in better control of their disease and their lives with a safe and effective treatment option.

Areteia is comprised of seasoned drug developers with deep regulatory, commercial, and supply-chain experience. The company has initiated worldwide phase 3 clinical trials in eosinophilic asthma with the goal of securing regulatory approvals for dexpramipexole's global commercialization. Their mission is to transform the challenging patient journey in eosinophilic asthma by providing an effective and well-tolerated oral treatment alternative to currently available injectable biologics.

Areteia Therapeutics is a clinical stage biotechnology company dedicated to developing and delivering the first oral drug for eosinophilic asthma. They are committed to putting respiratory patients in better control of their disease and back in control of their lives through the development of a safe and effective oral treatment for eosinophilic asthma, which is a type of asthma that is often severe and difficult to treat. Their mission is to transform the challenging patient journey in eosinophilic asthma by providing a convenient and effective treatment option.

Areteia Therapeutics cultivates a global, agile, and outcome-driven culture that values team members as both leaders and doers. Their commitment to developing and delivering the first oral drug for eosinophilic asthma is evident in their focus on innovation, collaboration, and a shared passion for improving patient lives. The company fosters a dynamic environment that encourages teamwork, creativity, and a dedication to achieving ambitious goals.

Areteia Therapeutics emphasizes building a global, agile, and outcome-driven team that values its members as both leaders and doers. Their website mentions a commitment to a diverse team, though details regarding specific initiatives or programs related to diversity, equity, and inclusion are not provided.